Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze

Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze

The widening gap between gross and net sales, known as the gross-to-net (GTN) bubble, poses a significant challenge for pharmaceutical manufacturers. This article examines how physician-led patient education can serve as a strategic tool to mitigate this erosion. With GTN reductions reaching hundreds of billions of dollars annually and drug channel contracting growing more complex, BD and regulatory teams need new levers to protect net revenue — and the physician's office may be one of the most underutilized.

Key Takeaways

• The gross-to-net bubble — the difference between a drug's list price and the actual revenue manufacturers realize after discounts, rebates, and chargebacks — reached $356 billion in 2024, a 7% increase over the prior year.
• Physician-led patient education can function as a GTN mitigation strategy by improving adherence, reducing inappropriate utilization, and reinforcing a drug's value proposition at the point of care — indirectly protecting net revenue.
• The stacking of discounts — from rebates, patient assistance programs, and supplemental concessions — is a primary driver of GTN erosion, demanding more sophisticated management from BD and market access teams.
• Regulatory teams must align patient education initiatives with FDA and EMA expectations around quality systems and consistent drug performance, particularly as new molecular entities reach the market at an accelerating pace.
• Business development, regulatory, and medical affairs functions must coordinate on GTN strategy — treating physician engagement as a cross-functional commercial asset rather than a siloed medical activity.

What Is Driving the Gross-to-Net Squeeze?

The term "gross-to-net bubble" was coined by the Drug Channels Institute to describe the widening gap between a drug's wholesale acquisition cost (WAC) — its list price — and the net revenue a manufacturer actually realizes after all concessions. According to estimates, gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the prior year.

This erosion is not driven by a single factor. It results from the stacking of multiple discount layers: rebates negotiated with Pharmacy Benefit Managers, patient assistance programs, supplemental concessions, and chargebacks. A single prescription may trigger a rebate obligation, a co-pay assistance payment, a distribution fee, and a wholesaler chargeback — all before the manufacturer sees a dollar of net revenue. Multiply that across thousands of prescriptions and the financial impact compounds.

The complexity is compounded by the fact that list prices have continued to rise even as net prices have stagnated or declined in many therapeutic classes. This divergence creates political and regulatory risk — and it means that every percentage point of GTN erosion has an outsized impact on the bottom line. Industry analyses have estimated that gross-to-net revenue leakage across the sector exceeds $90 billion annually, driven by misaligned incentives, contract complexity, and utilization waste.

How Does Physician-Led Patient Education Reduce GTN Erosion?

The connection between a physician's counseling and a manufacturer's net revenue is indirect but operationally significant. When physicians clearly communicate a drug's value proposition, proper usage, and expected outcomes, patients are more likely to adhere to therapy, stay on the prescribed regimen longer, and avoid the wasteful prescription changes or abandonments that quietly drain net revenue.

Consider the mechanism. Non-adherence generates its own form of GTN leakage: a drug that sits in a medicine cabinet produces no revenue, yet its initial sale may have triggered a rebate obligation, a PAP co-pay concession, or a distribution fee. Physician-led education — delivered during the clinical encounter, where trust is highest — can reduce that waste at its source.

There is also a quality dimension that ties directly to GTN outcomes. Quality control is an essential operation of the pharmaceutical industry. Drugs must be marketed as safe and therapeutically active formulations whose performance is consistent and predictable. New medicinal agents are being produced at an accelerated rate, and when patients do not understand how to use them correctly, real-world outcomes can diverge sharply from clinical trial results. That divergence weakens the value story that BD teams use in payer negotiations, potentially triggering steeper rebate demands — and deeper GTN erosion.

In this sense, physician-led education functions as a form of demand-side quality assurance. It ensures that the drug performs as intended in the real world, which in turn supports the evidence base that market access teams rely on to defend net pricing. Research published in PMC and related studies has examined how structured patient education delivered at scale helps align real-world utilization with the clinical and economic value that manufacturers articulate to payers.

What Are the Implications for Pharma BD and Regulatory Teams?

For business development teams, GTN pressure reshapes how deals get structured. Real-world drug performance depends on patients actually using the drug as directed — and that visibility depends on effective physician engagement. BD teams that invest in physician education infrastructure alongside their market access strategies may find they have stronger negotiating positions with payers, because the real-world evidence supports the drug's differentiated value.

The financial stakes are substantial. For individual brands, even modest improvements in adherence and appropriate use — achievable through physician-led education — can translate into meaningful net revenue protection at scale. In an environment where GTN leakage exceeds $90 billion annually across the sector, the ROI on education-focused interventions deserves serious analytical attention.

Regulatory considerations are equally important. The FDA emphasizes a quality systems approach, expecting manufacturers to build quality into their processes from development through commercialization. Patient education programs that reinforce appropriate use align with that expectation and can mitigate risks associated with off-label use or misuse — both of which can trigger adverse event reporting obligations, labeling scrutiny, and reputational damage that further erode commercial performance. The EMA applies similar expectations for products marketed in the European Union, requiring consistent risk communication across the product lifecycle.

Compliance in patient support programs also demands attention. As GTN management becomes more sophisticated, regulators and enforcement agencies are scrutinizing manufacturer-funded assistance programs for potential Anti-Kickback Statute exposure. BD and legal teams must ensure that any physician-led education initiative is structured independently of product promotion and complies with applicable regulatory frameworks.

The evolving drug channel landscape — including consolidation among PBMs and the growing influence of specialty pharmacy — means that GTN management can no longer be treated as a back-office finance function. It requires cross-functional coordination among BD, regulatory, medical affairs, and market access. Teams that treat physician-led education as a strategic asset rather than a tactical afterthought will be better positioned to protect net revenue in an increasingly squeezed environment.

Frequently Asked Questions

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial